Georgia Senate Candidate Proposes Patent Reform to Lower Prescription Drug Costs

By Gene Quinn
March 25, 2014

Art Gardner

Art Gardner, a Republican patent attorney seeking election to the U.S. Senate in Georgia, has recently proposed a reform to the nation’s patent laws to address the artificially high price of prescription medicines in the U.S.

Specifically, Gardner proposes to make it patent misuse to charge much more in the United States for the same drug than in the rest of the G7. According to Gardner, “it would be presumptive patent misuse to charge more than 125% of the average price in the other 6 countries in the G7 and it would be conclusive patent misuse to charge more than 150%.” This innovative change would be a simple change in the U.S. patent laws and would be very impactful. Said Gardner, “If the patent is being ‘misused’ in this way, the patent would be invalidated and/or unenforceable, opening up competition for generics. So the owner of a drug patent would have a strong interest in avoiding losing the protection of the patent and would hold down U.S. prices and/or drive up prices around the world.  Either way, we (the U.S. consumers) would over time end up paying the real price of patented medicines, not the exaggerated price which includes a subsidy for foreigner consumers.”

Patent misuse is currently a defense to enforceability of a patent. Gardner’s proposal would be a significant expansion of the patent misuse doctrine, and one that would no doubt face substantial hurdles since the pharmaceutical industry would be guaranteed to protest.

Still, Gardner does make an interesting point on some levels, which is one that we have made here in the past. US consumers subsidize cheaper drugs for the rest of the world, which is undoubtedly one of the reasons that health care costs are out of control.

“I have long considered it terribly wrong that we pay a monopolized market price for medicines covered by patents in the U.S., while in most other G7 countries the local (national) government sharply controls the maximum price that the pharmaceutical companies can charge. This causes consumers in the U.S. to pay much, much more for the same drugs as sold in other countries.” Indeed, this price disparity has created the cottage industry of people driving across the Mexico and Canada borders to buy cheaper drugs. Gardner goes on to say, “The net result is that the U.S. consumer is paying much more than he/she ought to and the foreign consumer is paying a good bit less than he/she ought to. So in effect, the U.S. consumer is subsidizing low drug costs for foreigners. To me, forcing the U.S. consumer to subsidize foreign drug prices is outrageous.”

Gardner was the only candidate on the Republican side who did not appeal in a recent poll. Although his campaign continues, at this point there is little reason to believe that he will achieve the nomination against the well known candidates at the top of the field. Seriously raising the question of controlling costs for prescription drugs could, however, get him some attention.

The Author

Gene Quinn

Gene Quinn is a Patent Attorney and Editor and founder of Gene is also a principal lecturer in the PLI Patent Bar Review Course and an attorney with Widerman Malek. Gene’s specialty is in the area of strategic patent consulting, patent application drafting and patent prosecution. He consults with attorneys facing peculiar procedural issues at the Patent Office, advises investors and executives on patent law changes and pending litigation matters, and works with start-up businesses throughout the United States and around the world, primarily dealing with software and computer related innovations. is admitted to practice law in New Hampshire, is a Registered Patent Attorney and is also admitted to practice before the United States Court of Appeals for the Federal Circuit. CLICK HERE to send Gene a message.

Warning & Disclaimer: The pages, articles and comments on do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author and should not be attributed to the author’s employer, clients or the sponsors of Read more.

Discuss this

There are currently 10 Comments comments.

  1. EG March 25, 2014 11:13 am


    With all due respect, what Gardner proposes is myopic. We don’t need to impose patent misuse and we do, there will be minimal, if any, investment in new drug development (most of which is now coming from smaller R&D companies, no big pharma).

    The problem here is that the rest of the world (ROW) imposes economically unrealistic price controls on drugs, and in the case of many countries such as India, Ireland, etc., compulsory licensing of patents covering drugs, whereas the US does not (and in my opinion, rightly so). Someone has to pay for the R&D for drug development (now anywhere from $1-4 billion), and because of price controls in the ROW, the US consumer is primarily the one to pay for that R&D.

    What the ROW does with price controls on drugs, as well as compulsory licensing, in my view, makes a mockery of GATT and TRIPS. And the ROW is also hypocritical in this regard because you should have heard them “scream” in the World Court at the Hague how our 337 Actions in the ITC for “unfair trade practices” resulting from imports infringing IP was a GATT violation. Unfortunately, our US Trade Representative is too chicken to hold our ROW partners “feet to the fire” for such hypocrisy.

  2. Gene Quinn March 25, 2014 11:56 am


    I completely agree with you. It is the price controls in the rest of the world that are the problem. That is what leads US consumers to subsidize cheap drugs for the rest of the world.

    I made that point specifically in this article:

    Something does need to be done about this. It is fundamentally unfair and unjust for Americans, many of whom are poor or on fixed incomes to be forced to either subsidize the rest of the world or violate US law by going to Canada for drugs.


  3. Anon March 25, 2014 12:44 pm

    What are the chances that any sense of geographical market segmentation will take a hit in the patent world as it did in the copyright world from the Kirtsaeng case?

    Another area to be careful for what one wishes for.

  4. Moshe March 25, 2014 2:30 pm

    This should be limited patents owned by companies from countries where there are government-imposed price-caps (or compulsory licensing) on pharmaceuticals If the Canadians want to impose price caps on drugs, then Canadian pharma companies will be forced to charge the G7 prices in the USA. If the Canadian pharma companies don’t like it, they can lobby their government. But the way it is proposed now, ethical pharma companies get punished TWICE — once by foreign gov’ts which cap the price of their products, and now in the USA where they cannot enforce their patents
    Foreign countries will have to choose between proper IP protection without price-caps/compulsory licensing OR having a vibrant pharmaceutical industry.

  5. MaxDrei March 26, 2014 4:17 am

    Remind me, how did the US Govt pressure Bayer into seeling CIPRO to it cheap? Oh yes, I remember:

    It was the threat of compulsory purchase, wasn’t it?

    Pots? Kettles? Or, putting it another way “My ends justify my means. Yours don’t. Sorry.”

  6. American Cowboy March 26, 2014 1:40 pm

    Good idea Moshe!

  7. American Cowboy March 26, 2014 1:42 pm

    By the way, I bet this Gardner fellow represents software companies who think every software patentee is an evil troll.

  8. ben ford March 27, 2014 12:40 pm

    When you filter out comments you disagree with that is censorship. We post ours across the web so you will be exposed.

  9. ben ford March 27, 2014 12:42 pm

    make that…When you filter out comments you disagree with OR YOUR FUNDING SOURCES OBJECT TO that is censorship. We post ours across the web so you will be exposed.

  10. Georgia on my mind March 28, 2014 3:16 pm

    American Cowboy – You are probably right. He’s only looking out for his best interests and the interests of his deep pockets.